Adicet Bio, Inc. (ACET) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Adicet Bio, Inc. is a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company's lead candidates are ADI-001 (autoimmune diseases) and ADI-270 (solid tumors). The company has no approved products and has not generated product revenue to date.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(30,478) | $(49,885) | $(88,395) | $(113,169) |
| Net Loss Per Share | $(0.34) | $(1.16) | $(1.02) | $(2.63) |
| Operating Expenses | $33,153 | $52,262 | $96,872 | $120,472 |
| Cash & Equivalents | $105,482 | $183,257 | $105,482 | $183,257 |
| Short-term Investments | $96,583 | $0 | $96,583 | $0 |
| Total Liquidity | $202,065 | $183,257 | $202,065 | $183,257 |
| Accumulated Deficit | $(469,167) | $(351,283) | $(469,167) | $(351,283) |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss for Q3 2024 decreased by approximately 39% compared to Q3 2023. This improvement is primarily due to the absence of a $19.5 million goodwill impairment charge recorded in Q3 2023.
- Operating Expenses: Total operating expenses decreased by 37% in Q3 2024 compared to the prior year, driven by the non-recurring impairment charge in 2023. Excluding the impairment, core operating expenses remained relatively flat.
- Capital Raise: In January 2024, the company completed an underwritten public offering and an at-the-market (ATM) offering, raising approximately $111 million in net proceeds. This significantly bolstered liquidity compared to the prior year.
- Investment Activity: The company invested approximately $96.6 million in short-term treasury securities during the nine months ended September 30, 2024, compared to no such investments in the prior year period.
Guidance, Outlook, and Risks
- Clinical Progress:
- ADI-001: Enrollment is open for lupus nephritis (LN). The company received FDA Fast Track Designation for LN in June 2024. Plans include expanding to systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and other autoimmune indications in 2025.
- ADI-270: Received FDA clearance for an IND in renal cell carcinoma (RCC) in June 2024 and Fast Track Designation in July 2024. Phase 1 trial initiation is expected in Q4 2024.
- Liquidity Outlook: Management expects current cash, cash equivalents, and short-term investments ($202.1 million) to fund operations for at least the next 12 months, potentially into the second half of 2026.
- Key Risks:
- China Operations: The company initiated R&D in China via a Variable Interest Entity (VIE) in May 2024. Risks include regulatory uncertainty regarding the Foreign Investment Law and data security laws.
- Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require substantial additional financing to complete development and commercialization.
- Manufacturing: Reliance on third-party suppliers and the complexity of manufacturing "off-the-shelf" allogeneic cell therapies pose supply chain risks.
Investor Verification Checklist
- Verify the timeline for patient enrollment and data readouts for the ADI-001 Phase 1 trial in lupus nephritis.
- Confirm the status of the China VIE structure and any potential regulatory hurdles under the 2024 Negative List regarding gene therapies.
- Monitor the burn rate and cash runway given the significant accumulated deficit of $469.2 million.
- Review the terms of the collaboration with Regeneron Pharmaceuticals, Inc., specifically regarding future milestone payments and royalty obligations.
- Assess the impact of the January 2024 equity offering on shareholder dilution and the remaining capacity under the Jefferies ATM program.